Context Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
CNTX$0.20+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $14,449,827 | $35,497,445 |
| Prepaid expenses and other current assets | 1,597,384 | 2,356,213 |
| Total current assets | 16,047,211 | 37,853,658 |
| Operating lease right-of-use asset | — | 51,967 |
| Property and equipment, net | 15,524 | 27,568 |
| Other assets | — | 32,750 |
| Total assets | $16,062,735 | $37,965,943 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,383,016 | $936,330 |
| Accrued expenses and other current liabilities | 1,808,699 | 2,216,169 |
| Operating lease liability - current | — | 55,078 |
| Total current liabilities | 4,191,715 | 3,207,577 |
| Total liabilities | 4,191,715 | 3,207,577 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 issued and outstanding at December 31, 2023 and December 31, 2022 | 15,966 | 15,966 |
| Additional paid-in capital | 79,909,644 | 78,832,779 |
| Accumulated deficit | (68,054,590) | (44,090,379) |
| Total stockholders' equity | 11,871,020 | 34,758,366 |
| Total liabilities and stockholders' equity | $16,062,735 | $37,965,943 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.